Our findings suggested a low all-grade incidence of CEs associated with HER2-targeted ADC and a lower incidence of severe CE or those leading to treatment discontinuation, which is consistent with current studies66, 70. This evidence concerns the gene ERBB2 and cat-eye syndrome.